Get the Stockscreener App
0.8001
1.49%
-0.0121
After Hours:
.81
0.0099
+1.24%
Oncolytics Biotech Inc stock is traded at $0.8001, with a volume of 942.55K.
It is down -1.49% in the last 24 hours and down -15.58% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$0.8122
Open:
$0.8011
24h Volume:
942.55K
Relative Volume:
0.64
Market Cap:
$95.50M
Revenue:
-
Net Income/Loss:
$-25.91M
P/E Ratio:
-3.1788
EPS:
-0.2517
Net Cash Flow:
$-22.73M
1W Performance:
-5.87%
1M Performance:
-15.58%
6M Performance:
-31.03%
1Y Performance:
-23.80%
1-Day Range:
$0.796
$0.8293
1-Week Range:
$0.796
$0.887
52-Week Range:
$0.77
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8001 | 96.94M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
Oncolytics Biotech Inc. (ONCY) Files 8-K Notice of Nasdaq Delisting or Listing Rule Deficiency – July 2026 - Minichart
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ONCY Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Viral Immunotherapy Gets FDA Fast Track for Anal Cancer Patients Without Options - Tech Times
Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com South Africa
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer - TradingView
FDA grants fast track status to Oncolytics’ anal cancer therapy - Investing.com
Investigational anal cancer therapy posts 30% response rate - Stock Titan
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial - Smartkarma
MSN Money - MSN
Oncolytics Biotech (ONCY) Edges Lower Amid Light Trading – Key Levels in FocusSign of Weakness - dars.gov.et
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com UK
Oncolytics Biotech shares climb ahead of planned FDA meeting on REO 033 trial (ONCY) - MSN
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com South Africa
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial By Investing.com - Investing.com Canada
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - The Globe and Mail
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
ONCY Should I Buy - Intellectia AI
Oncolytics Biotech Inc. Actuals & Estimates (NASDAQ:ONCY) - TradingView
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):